on the operator curve in Figure 1 . Negative LE and nitrite alone is less specific ], Specificity 0.859 [95% CI 0.858-0.859]).
INTRODUCTION AND OBJECTIVES: Nitrofurantoin (NF) is used to treat recurrent urinary tract infections (RUTI)
. Despite minimal data, the Beers criteria has cautioned against long-term use of NF in geriatric patients. This study reviews the safety and efficacy of chronic suppressive therapy with NF in neurogenic (NG) and nonneurogenic (NN) post-menopausal women.
METHODS: A query of the electronic medical record at a tertiary care institution yielded 11,200 charts of women aged 50-95 prescribed NF by over 75 providers from 2006-2018 in outpatient clinics. Charts from primary urology providers prescribing NF therapy for at least 3 consecutive months were further analyzed. Demographics, reason for initiation of NF, dose, duration, explanation of therapy interruptions, resistance, occurrence of adverse, comorbid conditions, urine culture, and relevant lab and imaging results were recorded. Start and stop dates of chronic suppressive therapy were tallied from the medication lists and cross-referenced with documentation by the provider for accuracy. Number of months on chronic suppressive therapy were summed. RESULTS: Of the 221 patients included, 167 (77%) were prescribed 100mg of NF. The most common indication for chronic NF therapy was RUTI prophylaxis. 104 (47%) patients developed cultures resistant to NF but only 4 were switched to an alternative suppressive therapy. 88 (40%) patients developed breakthrough UTI but only 10 were not restarted on NF (4 patients due to NF resistance). NG patients had a higher occurrence of catheter use (p[0.0008) but NN patients had an increased incidence of breakthrough UTI (p[0.0134). There was no difference in resistance rates between NG and NN groups (p[0.4361). No patients developed neuropathy, 1 developed liver dysfunction after 3.5 years of therapy, and 4 developed pulmonary symptoms after a mean use of NF for 3.5 years. None who developed chronic cough had chronic changes to their x-rays CONCLUSIONS: We conclude that post-menopausal women tolerate chronic NF suppressive therapy well with minimal risk of significant adverse events. NF is a safe and effective in the management of chronic RUTI in this patient population.
Source of Funding: None

MP71-15 PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY
INTRODUCTION AND OBJECTIVES:
Patients with an underlying urological diagnosis colonised with multidrug-resistant organisms (MDRO) such as ESBL are predisposed to recurrent UTIs. Treatment can be prolonged with higher mortality and cost compared to infection with sensitive organisms. In FMT, healthy donor stool is administered into the GI tract to restore the healthy gut microbiota. This is acknowledged as an effective treatment for recurrent Clostridium difficile infection, and now as an emerging method of eradicating MDROs. However, there are little data reporting on its therapeutic value in Urology.
METHODS: Retrospective analysis of culture positive urine isolates was obtained from 2015 to 2018 at a tertiary level service.
RESULTS: Between June 2015-January 2018, 2059 patients under the Urology service had a positive urine culture. 128 (6%) were positive for ESBL. 456 patients had more than one positive urine culture and of these, 62 (14%) had more than one ESBL UTI. This constituted 8% of all recurrent ESBL UTIs in the trust (806 total). 52/62 (84%) with recurrent ESBL UTIs had an underlying urological diagnosis, while 10/62 (16%) were purely managed for recurrent UTIs. 19/62 patients had more than one underlying diagnosis. 7/62 (11%) patients underwent urological reconstructive surgery, and 40/62 (65%) had long term prosthetic devices (stents,nephrostomies or catheters)in situ (Table 1) . Four patients received FMT via NG tube, Table 2 describes their outcome.
CONCLUSIONS: ESBL UTIs are highly prevalent in Urology and an underlying cause should always be investigated, as there is a high incidence of obstructive aetiologies. Our early experience of FMT for both decolonisation and prevention of transition of colonisation to infection with MDROs has shown FMT to be safe, well tolerated and effective therapy in urological management. The purpose of this review is to assess the literature on non-antibiotic prophylaxis for recurrent UTI, focussing on less recognised strategies, namely vaccination and intravesical therapy.
METHODS: Embase, Pubmed and the Cochrane Library were searched from January 2000 to August 2018 for articles on nonantibiotic prophylaxis for recurrent UTIs published in English language. The search was limited to human studies comprising adult subjects (>18 years) with no past medical history of urinary tract or renal disease (such as renal transplantation, spinal cord injury, neurogenic bladder, chronic bladder pain syndrome or overactive bladder). Papers investigating pregnant women were also excluded. The Oxford Centre for Evidence-based Medicine (OCEBM) Levels of Evidence March 2009 was utilised in analysing the literature. RESULTS: Database searching revealed 4109 studies and 124 abstracts were reviewed. There is compelling evidence of the efficacy of intravesical Hyaluronic Acid with or without chondroitin Sulphate for the prevention of recurrent UTI. We provide the evidence with an OCEBM level 1a-. Evidence for intravesical heparin is more limited with an OECBM level 4. We recommend large-scale RCTs are performed before definitive conclusions can be drawn. A number of oral and vaginal vaccines containing bacterial extracts are being tested for the prevention of refractory UTI. However, there is no reported data on the long-term efficacy. Furthermore, many of the included studies had unclear methodology. We award the evidence an OCEBM level 1a-. Urovac is a vaginal suppository containing 10 heat-treated bacterial species including 6 serotypes of E. coli. We award the evidence an OCEBM level 1a. Uromune is a sublingual spray containing the inactivated bacteria. Evidence supporting its use is rated level 2b but a randomised doubleeblind placebo-controlled trial is reportedly underway.
CONCLUSIONS: Recurrent UTI remains a pervasive and morbid condition difficult to manage. New treatments as highlighted in this review help to broaden the armentarium that can be offered to a patient. Formal evidence of the more historic treatments is more lacking in comparison to the newer vaccines that have been developed. However these treatments are supported by the far greater depth of experience on their use and safety. However it is vital in all cases to tailor the treatment to the patients individual needs and wishes.
Source of Funding: Nil
MP71-17 IMPROVING THE MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS IN WOMEN UNDER 30 e DOES CONSERVATIVE TREATMENT REALLY WORK?
Abdel Hamed, Lorna Cameron, Susanne McPhee, Louise Granger, Annette Bell, Elaine Crombie, Kate Larkin, Ross Clark, Holly Bekarma*, Ayr, United Kingdom INTRODUCTION AND OBJECTIVES: Recurrent UTI's (rUTI) in young women can be common and not only impact quality of life (QoL) but also service provision within urology departments. The extent to which these patients require investigation or treatment is variable. Our department changed practice to manage these women in a nurse led service with medical input as required. The aims of this study were to reduce invasive investigations, antibiotic use and attendance at consultant clinics whilst encouraging self-management.
METHODS: 102 patients were referred to the service between March 2016 and 2018. Patients were appointed to see a Nurse Continence Specialist, reviewed and data collected on number of culture proven infections. Patients were assessed for specific triggers, post void residual, bowel habit, lifestyle factors and weight. All patients had US kidneys arranged and if visible haematuria (VH) was noted, referred for flexible cystoscopy. All were given conservative advice leaflets (BAUS cystitis, NICE IBS, bladder training, toilet positions, pelvic floor exercise, intercourse positions and lubrication advice).
RESULTS: 72 women aged 15 to 29 years attended. Despite being referred as rUTI, 31 women had no culture proven samples and 16 had only 1 infection. 25 patients had at least 2 proven cultures with the maximum being 6.
Triggers were identified in 33 women; 28 (85%) sexual intercourse, 2 alcohol consumption, 2 infrequent voiding and 1 high post void residual. All women had US KUB requested; 60 were performed, of which 49 (82%) were normal. 11 identified an abnormality; none were considered causative for rUTI. 16 women reported VH of which 13 had flexible cystoscopy e 10 (77%) were normal and 3 identified abnormalities -tight meatus, schistosomiasis and cystitis cystica. In the 25 patients with 2 plus proven infections, results were analysed separately after 12 months of input. In those with 2 infections (14 patients) 86% had 0 or 1. Patients with 3 infections (6 patients), 66% had 0 or 1. Those with 4 infections (3 patients), 66% had no further and the 2 patients with 5 or 6 infections both patients had 0. Only 3/25 required prophylactic,
